PTN · XBRL financial data
Palatin Technologies financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (PTN's year ends in late June)
| In thousands of dollars | Oct 31, 2023 | Jan 31, 2024 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | †Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 350* | 0 | — | 0 | 0* | 8,848 | — | — | year only |
| Revenue from contracts with customers | — | — | — | — | — | — | — | — | — | 116 | 3,921 | 301* |
| Cost of revenue | — | — | 0 | 0* | — | — | — | — | — | — | — | — |
| Research and development | — | — | 7,160 | 4,672* | 5,744 | 3,429 | 3,755 | 1,970* | 2,526 | 4,320 | 3,517 | 2,006* |
| Selling, general and administrative | — | — | 2,033 | 4,004* | 2,021 | 1,682 | 1,474 | 2,633* | 1,661 | — | — | — |
| General and administrative | — | — | — | — | — | 1,682 | 1,474 | 2,633* | — | 3,125 | 1,984 | 2,714* |
| Total operating expenses | — | — | 9,218 | 8,692* | 7,765 | 2,611 | 4,813 | 2,271* | 4,186 | 7,445 | 5,502 | 4,721* |
| Operating income (loss) | — | — | (9,218) | (8,342)* | (7,765) | (2,611) | (4,813) | (2,271)* | 4,661 | (7,329) | (1,581) | (4,420)* |
| Interest expense | — | — | 1 | 3* | 6 | 4 | 2 | 3* | 2 | 0 | 1 | 3* |
| Other income (expense) | — | — | 783 | 92* | (59) | 169 | 2 | 41* | 16 | 65 | 148 | 61* |
| Income tax expense (benefit) | — | — | 0 | 0* | — | — | — | year only | — | — | — | year only |
| Net income (loss) | — | — | (8,436) | (8,250)* | (7,824) | (2,442) | (4,811) | (2,230)* | 4,678 | (7,264) | (1,433) | (4,359)* |
| Earnings per share, basic USD per share | — | — | — | — | (0.39) | (0.12) | (9.13) | — | 4.81 | (2.86) | (0.37) | — |
| Earnings per share, diluted USD per share | — | — | (0.53) | — | (19.71) | (5.92) | (0.18) | — | 4.26 | (2.86) | (0.37) | — |
| Weighted average shares, basic thousands of shares | — | — | — | — | 19,845 | 20,635 | 527 | — | 972 | 2,540 | 3,912 | — |
| Weighted average shares, diluted thousands of shares | — | — | 15,792 | — | 397 | 413 | 26,345 | — | 1,098 | 2,540 | 3,912 | — |
- † Share count changed about 1/48 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (PTN's year ends in late June)
- † Share count changed about 1/48 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (PTN's year ends in late June)
| In thousands of dollars | Oct 31, 2023 | Jan 31, 2024 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | †Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | — | — | (8,436) | (8,250)* | (7,824) | (2,442) | (4,811) | (2,230)* | 4,678 | (7,264) | (1,433) | (4,359)* |
| Stock-based compensation | — | — | 390* | 542* | 349 | 349 | 348* | 337* | 168 | 311* | 420* | 431* |
| Net cash from operating activities | — | — | (8,607)* | (6,472)* | (7,016) | (4,847)* | (5,354)* | (4,089)* | (1,619) | (4,807)* | (4,417)* | (2,690)* |
| Purchases of property and equipment | — | — | 0* | 5* | — | — | 0* | 0* | — | — | 38* | 0* |
| Net cash from investing activities | — | — | 0* | (5)* | 0 | 2,500* | 0* | 630* | — | — | (38)* | 0* |
| Proceeds from issuing common stock | — | — | 9,163* | (28)* | 0 | 0* | 4,458* | 3,503* | — | — | (1)* | 0* |
| Net cash from financing activities | — | — | 9,136* | 5,991* | (127) | 3,379* | 4,458* | 3,503* | 328 | 18,023* | 139* | 23* |
- † Share count changed about 1/48 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Palatin Technologies | 7,492 | 301* | (2,690)* | 1.8M | 2.8 quarters | 10-KJun 30, 2026 |
| Scynexis | 10,487 | 235 | (14,885)* | 9.9M | 3.6 quarters | 10-QJun 30, 2026 |
| Pulmatrix | 2,168 | not reported | (1,106)* | 3.7M | 2.0 quarters | 10-QJun 30, 2026 |
| Curis | 5,073 | 0 | (9,646)* | 2.1M | 0.5 quarters | 10-QJun 30, 2026 |
| Kala Bio | 229 | not reported | (1,535)* | 19.3M | 4.7 quarters | 10-QJun 30, 2026 |
| Lexaria Bioscience | 3,500 | 0 | (1,635)* | 24.8M | 2.2 quarters | 10-QMay 31, 2026 |
| Outlook Therapeutics | 11,242 | not reported | (21,011)* | 243.4M | 0.5 quarters | 10-QJun 30, 2026 |
| Dyadic International | 1,425 | 961 | (1,818)* | 36.4M | 1.7 quarters | 10-QJun 30, 2026 |
| Aytu Biopharma | 26,308 | 16,106* | 4,406* | 10.9M | — | 10-KJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.